glp-1 cancer risk No Increased for Thyroid in Diabetic Patients Prescribed Medications Compared to Those Prescribed Insulin GLP-1s in Oncology: Exploring Risks
Description
Oral GLP-1 RA in Development The success of orally administered semaglutide in clinical trials has led to the development of other oral formulations
Methods Design This was a qualitative study using individual semi-structured interviews
The twice-daily dosing requirement and gastrointestinal side effects have limited its use compared to newer, longer-acting alternatives
Avoiding strength training
See the full release here
